Focus Partners Advisor Solutions LLC Buys 13,579 Shares of Medtronic PLC $MDT

Focus Partners Advisor Solutions LLC grew its position in shares of Medtronic PLC (NYSE:MDT) by 72.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,428 shares of the medical technology company’s stock after purchasing an additional 13,579 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Medtronic were worth $3,030,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic in the third quarter valued at $29,000. Delos Wealth Advisors LLC bought a new stake in Medtronic in the second quarter worth $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic in the third quarter worth $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic during the third quarter valued at $34,000. 82.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MDT. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Royal Bank Of Canada boosted their price objective on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Daiwa Securities Group lowered their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Citigroup began coverage on Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 target price for the company. Finally, CICC Research started coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.74.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Stock Performance

Shares of Medtronic stock opened at $95.58 on Thursday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock’s fifty day moving average is $98.89 and its two-hundred day moving average is $96.98. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a market capitalization of $122.71 billion, a PE ratio of 26.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).